On this page
What is Helicobacter Pylori?
Helicobacter pylori (H. pylori) is a type of bacteria capable of infecting and colonizing the human stomach. It is one of the most common bacterial infections worldwide, estimated to affect approximately 50% of the global population, though prevalence varies significantly between developed and developing countries.
What makes this microorganism particularly resilient is its remarkable ability to survive the highly acidic environment of the stomach. It does so by producing an enzyme called urease, which converts urea into ammonia. This ammonia neutralizes the surrounding gastric acid, creating a protective “bubble” that allows the bacterium to thrive and burrow into the stomach lining.
In many cases, H. pylori causes no symptoms at all, and most infected individuals never know they carry the bacterium. However, in a subset of patients, the infection can trigger significant gastrointestinal problems, including:
- Frequent belching
- Stomach burning and bloating
- Nausea and a persistent feeling of fullness
- Loss of appetite
- Unexplained weight loss
Treatment involves a combination of stomach-protective medications (proton pump inhibitors) and multiple antibiotics taken simultaneously, a strategy known as eradication therapy.
How the Infection Spreads
H. pylori infection occurs when bacteria successfully colonize the stomach lining. Although the exact routes of transmission are not fully understood, research points to several key pathways:
-
Direct person-to-person contact: The most common route. The bacteria can be transmitted through direct exposure to saliva, vomit, or feces from an infected individual. This makes close household contact, such as that between family members, a significant risk factor.
-
Contaminated food and water (oral-fecal route): Consumption of contaminated water, undercooked meat, unwashed vegetables, or unpasteurized milk has been associated with transmission in some studies. This route is more common in areas with poor sanitation.
-
Childhood acquisition: Infection is most commonly acquired during childhood, often in overcrowded living conditions with limited access to clean water and sanitation.
Should family members be tested? According to current evidence, routine screening of family members of a newly diagnosed patient is generally not considered necessary. Exceptions include specific situations, such as frequent reinfections, recurrences, or a strong family history of gastric cancer.
Symptoms
One of the most striking aspects of H. pylori infection is that only about 1 in 5 infected people develops noticeable symptoms or complications. The vast majority of carriers remain completely asymptomatic, yet they can still transmit the bacteria and are at long-term risk for complications.
When symptoms do occur, they typically resemble those of gastritis or peptic ulcer disease, and may include:
- Abdominal burning that worsens on an empty stomach
- Abdominal pain, especially in the upper-middle region of the belly
- Nausea and vomiting
- Difficulty digesting food (dyspepsia)
- Loss of appetite
- Frequent belching
- Bloating
- Unintentional weight loss
- Bad breath (halitosis)
When should you see a doctor? Seek prompt medical attention if you experience severe or persistent stomach pain, blood in your vomit or stool, or black and tarry stools. These are warning signs that require immediate evaluation.
Complications
While many H. pylori infections remain harmless, chronic infection can lead to serious complications if left untreated.
Stomach Ulcer
H. pylori is the leading cause of peptic ulcers worldwide. The bacteria damage the protective mucosal lining of the stomach and the upper part of the small intestine (duodenum), allowing gastric acid to erode the underlying tissue and form open sores called ulcers.
The hallmark symptom of a peptic ulcer is a gnawing or burning pain in the area between the ribs and the navel. This pain often:
- Improves temporarily after eating (as food buffers the acid)
- Returns a few hours later
- Is severe enough to wake patients from sleep at night
If ulcers bleed, they can cause:
- Hematemesis: vomiting blood (which may look bright red or like coffee grounds)
- Melena: black, tarry stools indicating digested blood
- Anemia: due to chronic blood loss
Bleeding ulcers are a medical emergency and require immediate hospital care.
Stomach Cancer
The relationship between H. pylori and gastric cancer is complex and depends on the location of the tumor within the stomach:
-
Non-cardia gastric cancer (affecting the body of the stomach, antrum, or pylorus): H. pylori infection is a well-established major risk factor, classified by the World Health Organization (WHO) as a Group 1 carcinogen. Eradicating the bacteria significantly reduces this risk.
-
Cardia gastric cancer (affecting the upper part of the stomach near the esophagus): The role of H. pylori here is more nuanced. In some individuals, the bacteria may have a neutral or even potentially protective effect for this specific cancer type.
This distinction is clinically important, as it influences how we interpret the overall risk associated with the infection.
Beyond gastric adenocarcinoma, H. pylori has also been linked to a rare type of stomach lymphoma called MALT lymphoma (mucosa-associated lymphoid tissue lymphoma), which can often regress completely with successful eradication of the bacteria.
Diagnosis
The identification of H. pylori infection today follows precise, evidence-based protocols. Non-invasive tests are preferred for initial diagnosis and for confirming eradication after treatment, while invasive methods are reserved for selected cases or when “alarm symptoms” are present.
Important preparation before any test: To ensure reliable results, patients must:
- Stop taking antibiotics at least 4 weeks before the test
- Stop taking proton pump inhibitors (PPIs) (such as omeprazole or pantoprazole) at least 2 weeks before the test
Failure to follow these instructions can lead to false-negative results, meaning the infection is missed.
Non-Invasive Tests
Non-invasive tests are the first-line choice for most patients, particularly younger individuals without alarm symptoms.
-
Urea Breath Test (UBT): Considered the gold standard for accuracy. The patient drinks a solution containing urea labeled with a carbon isotope (C-13). If H. pylori is present in the stomach, its urease enzyme breaks down the urea, releasing labeled carbon dioxide. This CO₂ is absorbed into the bloodstream and exhaled, where it can be detected by analyzing the patient’s breath in a collection bag or tube. The test is highly sensitive and specific, non-invasive, and provides rapid results. For detailed procedural information, see the dedicated guide on the breath test for Helicobacter pylori.
-
Stool Antigen Test (SAT): This test directly detects H. pylori proteins (antigens) in a stool sample using specific antibodies. It is extremely reliable, with sensitivity and specificity comparable to the breath test. This method is particularly well-suited for children and patients who have difficulty performing the breath test. It is also the preferred method for confirming eradication in some clinical settings.
-
Serological Blood Test (IgG Antibody Test): Detects the presence of IgG antibodies against H. pylori in the blood. While simple to perform, this test cannot distinguish between a current active infection and a past infection that has already resolved, because antibodies can persist in the bloodstream for months to years after successful eradication. For this reason, its use in current clinical practice is significantly limited and generally not recommended for post-treatment confirmation.
Invasive Methods
Gastroscopy (upper gastrointestinal endoscopy) remains the reference examination when direct visualization of the gastric mucosa is necessary. It is indicated when the patient presents alarm symptoms such as:
- Unexplained weight loss
- Iron-deficiency anemia
- Gastrointestinal bleeding
- Progressive difficulty swallowing
- Age over 45-50 with new-onset dyspepsia (depending on national guidelines)
- Suspected malignancy
During the procedure, the physician inserts a flexible tube with a camera through the mouth to examine the esophagus, stomach, and duodenum. Small tissue samples (biopsies) are collected for the following analyses:
-
Rapid Urease Test (RUT): A biochemical test performed immediately after the biopsy. The tissue sample is placed in a medium containing urea; if H. pylori is present, urease activity changes the color of the medium, providing a result within a few hours.
-
Histological Examination: Microscopic analysis by a pathologist to evaluate the degree of inflammation (gastritis), the presence and density of H. pylori organisms, and to rule out pre-cancerous or cancerous changes in the mucosa.
-
Culture and Antibiogram: This test grows the bacteria from the biopsy sample in a laboratory to identify which antibiotics it is susceptible or resistant to. It is rarely performed as a first-line test, but becomes essential after the failure of two or more treatment cycles, as it guides the selection of an effective “rescue” therapy tailored to the patient’s specific bacterial strain.
Treatment and Cure
The primary goal of therapy is the complete eradication of H. pylori (meaning the total elimination of the bacteria from the stomach). Successful eradication allows the gastric mucosa to heal, prevents ulcer recurrence, and significantly reduces the long-term risk of gastric cancer.
Due to the increasing global resistance of H. pylori to antibiotics (particularly to clarithromycin and metronidazole), therapeutic strategies have evolved toward more robust, multi-drug regimens administered over longer periods than previously recommended.
Pharmacological Protocols
Treatment choice is guided by:
- Local antibiotic resistance patterns in the region
- The patient’s previous antibiotic exposure
- Known drug allergies
Current national and international guidelines, including those from the European Helicobacter and Microbiota Study Group (Maastricht VI Consensus), recommend treatment durations of 14 days in almost all cases. This is because shorter courses, such as 7 or 10 days, are linked to lower eradication rates.
First-Line Treatment Options
-Bismuth Quadruple Therapy (BQT): Now considered a preferred first-line treatment in many countries and across much of Europe. This regimen combines:
- proton pump inhibitor (PPI) (e.g., omeprazole or pantoprazole), twice daily
- Bismuth subcitrate, which exerts a direct bactericidal effect on H. pylori and helps overcome antibiotic resistance -Metronidazole, an antibiotic
- Tetracycline, an antibiotic
The last three components are often available as a single combined capsule (e.g., Pylera®), taken four times daily, simplifying adherence. The bismuth component is particularly valuable because it works through a mechanism independent of conventional antibiotics, making it effective even against partially resistant strains.
The last three components are often available as a single combined capsule (e.g., Pylera®), taken four times daily, simplifying adherence. The bismuth component is particularly valuable because it works through a mechanism independent of conventional antibiotics, making it effective even against partially resistant strains.
-
Concomitant Quadruple Therapy (Non-Bismuth): An alternative first-line option where the patient takes all four drugs simultaneously:
- A PPI twice daily
- Amoxicillin
- Clarithromycin
- Metronidazole
This approach is preferred in areas where clarithromycin resistance remains below 15%, though its global use is declining due to rising resistance rates.
The Role of Proton Pump Inhibitors (PPIs)
Gastroprotective drugs such as omeprazole or pantoprazole are an indispensable component of every H. pylori eradication regimen. They serve a dual purpose:
- Protect the gastric mucosa from further acid damage during healing.
- Enhance antibiotic efficacy: By raising stomach pH, PPIs create an environment where antibiotics, particularly amoxicillin and clarithromycin, are more stable. This makes them more effective at killing the bacteria.
PPIs are generally prescribed as gastroprotective agents twice daily throughout the entire treatment course.
Rescue Therapies for Treatment Failure
If the first eradication attempt fails, the physician will prescribe a “rescue” or “salvage” therapy. Options include:
- Regimens incorporating levofloxacin, a fluoroquinolone antibiotic
- Rifabutin-based triple therapy, reserved for multi-drug resistant cases
- Culture-guided therapy based on antibiogram results from a biopsy, which precisely identifies the most effective antibiotic for the patient’s specific bacterial strain
Never self-medicate or stop therapy early: Incomplete antibiotic courses are a leading cause of antibiotic resistance. Always follow your doctor’s instructions and complete the full prescribed duration.
Lifestyle Support During Therapy
To maximize eradication success rates and minimize side effects (which commonly include diarrhea, metallic taste, nausea, or abdominal discomfort), the following practical measures are strongly recommended alongside pharmacological treatment:
-
Probiotics: Supplementation with specific probiotic strains, particularly Saccharomyces boulardii and certain Lactobacillus species, during and after the antibiotic course has been shown in multiple clinical trials to significantly reduce gastrointestinal side effects and improve patient adherence to the full treatment course. Consult your physician about the appropriate probiotic strain and timing.
-
Dietary adjustments:
- Eat small, frequent meals to prevent prolonged periods of an empty stomach, which worsens acid irritation
- Avoid spicy foods, fried or fatty foods, alcohol, and coffee, all of which can aggravate gastritis symptoms
- Focus on easily digestible, bland foods during the treatment period
-
Medications to avoid: It is critical to limit or avoid the use of:
- Aspirin
- Ibuprofen
- Other non-steroidal anti-inflammatory drugs (NSAIDs) (anti-inflammatory drugs)
These medications independently damage the gastric mucosal lining and dramatically increase the risk of bleeding in patients with H. pylori-related gastritis or ulcers. If pain relief is needed, paracetamol (acetaminophen) is generally a safer alternative. You should consult your doctor.
-
Alcohol abstinence: Alcohol should be completely avoided during the treatment period, as it can interact with certain antibiotics (particularly metronidazole) and worsen mucosal irritation.
Confirming Eradication: The Post-Treatment Test
After completing therapy, it is essential to confirm that the infection has been successfully eliminated. Guidelines recommend:
- Waiting at least 4 to 6 weeks after finishing all medications (both antibiotics and PPIs) before performing a follow-up test.
- To confirm eradication, you can use either the urea breath test or the stool antigen test. Blood antibody tests, however, are not suitable for this purpose because antibodies remain detectable long after successful treatment.
If the post-treatment test is positive, the patient should be referred back to their physician for a rescue therapy plan.
Sources and Bibliography
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) on NIH.gov: Peptic Ulcers & H. pylori
- Retroflexions: How Did I Get an H. pylori Infection?
- Mayo Clinic H. pylori infection: Symptoms & Causes
- National Cancer Institute - H. pylori and Cancer Fact Sheet
- PMC H. pylori transmission via saliva (NCBI)
- Emerging Infectious Diseases: H. pylori transmission via vomit (CDC)
- PMC H. pylori transmission via feces (NCBI)
- PubMed Food-borne transmission of H. pylori
- PubMed: Family member screening in H. pylori
- AIRC: Helicobacter pylori, enemy or ally?
- Malfertheiner P, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence Consensus Report. Gut. 2022. DOI: 10.1136/gutjnl-2022-327745
- World Health Organization (WHO), IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 61: Schistosomes, Liver Flukes and Helicobacter pylori. Lyon: IARC, 1994.
